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Objectives: To give an overview of the genetic and structural abnormalities occur-
ring in fetuses with nuchal translucency (NT) measurement exceeding the 95th per-
centile at first‐trimester screening and to investigate which of these abnormalities
would be missed if cell‐free fetal DNA (cfDNA) were used as a first‐tier screening test
for chromosomal abnormalities.
Methods: This is a national study including 1901 pregnancies with NT≥95th per-
centile referred to seven university hospitals in the Netherlands between 1 January
2010 and 1 January 2016. All cases with unknown pregnancy outcome were
excluded. Results of detailed ultrasound examinations, karyotyping, genotyping, preg-
nancy and neonatal outcomes, investigation by a clinical geneticist and post‐mortem
investigations were collected.
Results: In total, 821 (43%) pregnancies had at least one abnormality. The rate of
abnormalities was 21% for fetuses with NT between 95th and 99th percentile and
62% for fetuses with NT≥99th percentile. Prevalence of single‐gene disorders, submi-
croscopic, chromosomal and structural abnormalities was 2%, 2%, 30% and 9%,
respectively.
Conclusion: Although cfDNA is superior to the combined test, especially for the
detection of trisomy 21, 34% of the congenital abnormalities occurring in fetuses
with increased NT may remain undetected in the first trimester of pregnancy, unless
cfDNA is used in combination with fetal sonographic assessment, including NT
measurement.1 | INTRODUCTION
Nuchal translucency (NT), defined as the subcutaneous accumulation
of fluid behind the fetal neck, can effectively be measured by an- - - - - - - - - - - - - - - - - - - - - - - - - -
the Creative Commons Attributio
d, the use is non‐commercial and
by John Wiley & Sons Ltdultrasound investigation between 11 and 13+6 weeks of gestation.
Nuchal translucency was first described in 1992 by Nicolaides1 as a
marker for fetal chromosomal abnormalities and especially Down syn-
drome. Since its first appearance in the prenatal screening paradigm,- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
n‐NonCommercial‐NoDerivs License, which permits use and distribution in any
no modifications or adaptations are made.
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What's already known about this topic?
• Nuchal translucency is associated with a wide range of
chromosomal and structural abnormalities.
What does this study add?
• If cell‐free DNA were used as the only first trimester
screening test, 34% of fetal congenital abnormalities
would be missed in the first trimester of pregnancy.
• In high‐risk pregnancies with increased nuchal translu-
cency (NT≥95th percentile), 23% of abnormalities are
found in fetuses with NT between 95th and 99th
percentile.
2 BARDI ET AL.many authors have studied the value of NT measurement for the
detection of fetal congenital abnormalities and it is now well
established that an increased NT (defined as NT≥3.5 mm – corre-
sponding to the 99th centile) is not only associated with chromosomal
abnormalities but also with a wide range of structural defects2,3 and
genetic aberrations.2,4,5 In the Netherlands, NT measurement is
offered since 2007 as part of the first trimester combined test (CT).
Since 2017, genome‐wide cell‐free fetal DNA (cfDNA) has become
the preferred first tier screening test for fetal aneuploidies, next to
the CT. Women are informed on the test characteristics of the two
tests and, owing to the better performance6 of cfDNA, the lower false
positive rates7-11 and the possibility to detect large fetal chromosomal
aberrations,12 the proportion of women choosing for the CT has dra-
matically dropped.13 Now the CT is mainly performed in di‐chorionic
multiple pregnancies. Women choosing for cfDNA generally undergo
a dating scan at around 10 weeks’ gestation. This means that, although
an enlarged NT (≥99th percentile) and fetal abnormalities are consid-
ered exclusion criteria for cfDNA, the lack of a systematic scan at
12‐13 weeks prevents the application of these exclusion criteria.
Before endorsing this change in first trimester screening policy it is
important to assess, once more, the role of the NT measurement as
marker for congenital abnormalities that cannot be detected by
cfDNA. In this study we aim at doing so on a national dataset obtained
before the introduction of cfDNA, when the CT was still being offered
as the only screening test during the first trimester of pregnancy.2 | METHODS
2.1 | Population
This is a retrospective cohort study including 1901 pregnancies with a
nuchal translucency measurement exceeding the 95th percentile,
measured at 11‐13+6 weeks’ gestation, between 1 January 2010
and 1 January 2016 and referred to one of seven university hospitals
in The Netherlands (University Medical Center Groningen, Maastricht
University Medical Center, University Medical Centers Amsterdam
location VU and AMC, Leiden University Medical Center, Erasmus
Medical Center Rotterdam and Radboud University Medical Center
Nijmegen). In the Netherlands first trimester CT and NT measure-
ments are performed by sonographers accredited for the performance
of the scan14 and working in ultrasound clinics or in fetal medicine
units (FMU). Increased NT was defined as a measurement ≥95th per-
centile by CRL‐adjusted percentiles (CRL range 45‐84 mm), in accor-
dance to the standards of the FMF.15 According to the Dutch
screening protocol, a NT≥3.5mm (corresponding to the 99th percen-
tile) is an indication for referral to a tertiary‐care center for further
investigation in the form of additional ultrasound scans and genetic
testing, irrespective of the CT risk and of whether parents decline
karyotyping. The CT risk cut‐off used in the Netherlands is 1:200.
Fetuses with NT 95th‐99th percentile and CT risk lower than 1:200
are not referred for karyotyping, except in case of suspicion of fetal
abnormalities. In our study, pregnancies with NT 95th‐99th percentiletherefore included women referred after the CT either in view of an
increased CT risk or because of suspicion of congenital abnormalities
or women undergoing a first trimester scan at one of the FMUs
because of increased a‐priori risk for congenital abnormalities. The
dataset of one of the seven university centers only included patients
with NT≥3.5 mm (n=67) referred from other ultrasound clinics in the
region, as the center did not perform first trimester screening.
All NT measurement ≥95th percentile by CRL‐adjusted percentiles
recorded in the study period were retrieved from local databases. Only
cases with known pre‐ and postnatal information, with emphasis on
results of detailed ultrasound examination, karyotyping by amniocen-
tesis or chorionic villous sampling (CVS), chromosomal microarrays
(CMA), delivery reports, post‐mortem examination and neonatal phys-
ical examination by a clinical geneticist of babies with visible abnormal-
ities at birth, were included and analyzed. Genetic testing, in the form
of QF‐PCR or karyotyping was offered to all mothers with an increased
risk at the CT defined as equal to or more than 1:200. Chromosomal
microarray (CMA) investigation was offered in case of NT≥3.5mm
and/or fetal structural abnormalities at the ultrasound investigation.
All centers used a cut‐off of 5MB for CMA, except for one center using
a cut‐off of 0.15MB. As the study covered six year the availability and
indications for CMA analysis changed in the course of the study. More-
over, not all the centers used the same protocols for offering CMA
investigation, especially when the increased NT was isolated.
2.2 | Data analysis
Maternal and clinical data locally stored in the clinical databases
(Astraia software gmbh and Mosos Clinical record) of the academic
hospitals were collected and transferred into a single electronic data-
base. SPSS Statistics Version 23.0 (IBM Corporation, NY, USA) was
used to perform descriptive and comparative statistics.
2.3 | Ethical statement
This study has been approved by the Medical Ethical Committee of
the University Medical Center of Groningen.
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In the study period, a total of 23494 NT measurements were recorded
in the databases of the seven medical centers. After exclusion of all
cases with NT<95th percentile (n=21486, 91.5%), 2008 (8.5%) fetuses
with NT≥95th percentile were included in the analysis. One‐hundred
(5%) cases were excluded because of missing follow‐up and 7 cases
were excluded because of lack of a final diagnosis. In total 1901 preg-
nancies with a NT≥95th percentile (Figure 1) were analyzed. Mean
maternal age at the time of NT measurement was 34 years (range 18‐
48) and the median NT was 3.6 mm (IQR: 2.8 – 5.1 mm). Of all fetuses
with NT≥95th percentile, 894 (47%) had a NT between 95th and 99th
percentile and 1007 (53%) had a NT≥95th percentile (Table 1).3.1 | Congenital abnormalities
In total, 814 (43%) pregnancies had at least one abnormality. Abnor-
malities were observed in 21.3% (n=190) of fetuses with a NTFIGURE 1 Flowchart patient populationbetween 95th and 99th percentile and in 62% (n=624) of cases with
a NT≥99th percentile. Among fetuses with NT≥99th percentile, the
percentage of congenital abnormalities exponentially increased from
43.3% (n=213) in cases with a NT between 3.5 and 4.9 mm to
79.6% (n=129) when NT was ≥8.0 mm (Table 1).3.2 | Genetic abnormalities
Of all fetuses, 33.3% (n=636) had genetic abnormalities (Table 1).
Chromosomal abnormalities were diagnosed in 29.4% (n=560) of
cases. Single‐gene disorders (Table 2) in 2% (n=38) and submicroscopic
genetic aberrations smaller than 5 Mb also in 2% (n=38) of fetuses
(Table 3). Among chromosomal abnormalities, trisomy 21, 18 and 13
were observed in 272 (45.5%), 134 (22.4%) and 50 (8.4%) cases,
respectively . In the remaining cases, other aneuploidies and karyotype
abnormalities (17.4%, n=104) were found (Table 4). Other genetic dis-
orders were especially present at higher degrees of NT enlargement.
TABLE 1 Congenital abnormalities associated with increased NT
NT
(mm)
All
fetuses
Congenital abnormality n (%)
All
abnormal
fetuses
Detected genetic abnormality (n=636, 33.3%)
Structural
(n=178,
9.3%)
Chromosomal (n=560, 29.4%)
Submicroscopic‡
Single‐
gene
disorders§Total T21‐18‐13* Other¶
p95‐p99 894 (47) 190 (21.3) 124 (13.8) 112 (12.5) 12 (1.3) 8 (0.9) 5 (0.6) 53 (5.9)
≥p99 1007 (53) 624 (62) 436 (43.2) 344 (34) 92 (9.1) 30 (3) 33 (3.3) 125 (12.4)
3.5‐4.9 492 (26) 213 (43.3) 138 (28) 122 (24.7) 16 (3.2) 16 (3.2) 6 (1.2) 53 (10.8)
5.0‐6.4 199 (10.5) 153 (76.8) 113 (56.8) 87 (43.5) 26 (13) 7 (3.5) 11 (5.5) 22 (11)
6.5‐7.9 155 (8.2) 129 (83.2) 93 (60) 79 (50.6) 14 (9) 5 (3.2) 4 (2.6) 27 (17.3)
≥8.0 162 (8.5) 129 (79.6) 92 (56.7) 56 (34.4) 36 (22.1) 2 (1.2) 12 (7.4) 23 (14.1)
Total 1901 814 (43) 560 (29.4) 456 (23.9) 104 (5.4) 38 (2.0) 38 (2.0) 178 (9.3)
*Trisomy 21 (n=272), trisomy 18 (n=134), trisomy 13 (n=50).
¶Other chromosomal abnormalities detected by classic karyotyping (Table 4).
‡Submicroscopic aberrations <5Mb detectable only by chromosomal microarrays.
§DNA sequence variations causing single‐gene disorders detectable by sequencing.
TABLE 2 Single‐gene disorders in the study population
Monogenic disease (gene) Total P95‐p99 ≥p99
Rasopathies ‐ total 20
‐Noonan syndrome ‐ total 18 4 14
Noonan syndrome (SOS1) 5 2 3
Noonan syndrome (PTPN11) 8 2 6
Noonan syndrome (LZTR1) 1 1
Noonan syndrome (RIT1) 3 3
Noonan syndrome (BRAF) 1 1
‐Leopard syndrome (PTPN11) 1 1
‐Cardio‐facio‐cutaneous syndrome
(MAP 2K1)
1 1
KAT6A Syndrome (KAT6A) 1 1
Pena‐Shokeir syndrome (NEB) 1 1
Cornelia de Lange syndrome (NIPBL) 2 1 1
Roberts syndrome (ESCO2) 2 2
Congenital abnormalities of the kidney and
urinary tract (KIF14)
1 1
Beals syndrome (FBN2) 1 1
Spinal muscular atrophy type 1 (SMN1) 1 1
Alpha‐thalassemia x‐linked intellectual
disability syndrome (ATRX)
1 1
Kabuki syndrome (KDMA6) 1 1
Zellweger syndrome (PEX1) 1 1
Donnai‐Barrow syndrome (LRP2) 1 1
APERT syndrome (FGFR2) 1 1
Mitochondrial myopathy, encephalopathy,
lactic acidosis, and stroke (MELA)
1 1
Multiple pterygium syndrome (CHRNG) 1 1
38 8 30
4 BARDI ET AL.Of the 38 single‐gene disorders, 20 (52%) were RASopathies (Table 5).
3.3 | Fetal structural abnormalities after genetic
anomalies are ruled out
Structural abnormalities were diagnosed in 178 (9.3%) chromosomally
normal fetuses. Of the isolated structural abnormalities, cardiac
defects were the most common ones (n=74, 3.9%), followed by abnor-
malities of the urogenital tract (n=20, 1%) and of the central nervous
system. Body stalk anomaly was diagnosed in 11 fetuses (0.6%)
(Table 6). Multiple congenital abnormalities were diagnosed in 29
fetuses (1.6%). Almost half of the structural defects (n=79, 44.4%)
were diagnosed at the time of the NT scan, between 11 and 13+6
weeks of gestation, and another 20.2% (n=36) at the moment the
pregnancy was referred to a fetal medicine unit (FMU) for fetal
karyotyping. This was in all cases before 18 weeks’ gestation. Espe-
cially abdominal wall defects were amenable to early diagnosis (detec-
tion rate (DR) at the NT scan: 7/9, 77.8%). Of the cardiac
abnormalities 21/74 (28.4%) had already been diagnosed at the early
scan and another 20/74 (27%) at referral to a tertiary center before
18 weeks’ gestation. Finally 26/74 (35%) were diagnosed after 18
weeks. Overall, 64.6% (n=115) of all structural abnormalities were
diagnosed before 18 weeks’ gestation. Table 6 shows the mean age
at termination of pregnancy (TOP) depending on the moment of diag-
nosis of the abnormalities. The majority of abnormalities (n=79) were
detected at NT measurement and the largest number of TOP (n=45)
occurred at a mean gestational age of 15 weeks +3 days (Table 6).
3.4 | NT cut‐off: 95th‐99th percentile
Receiver operating characteristic (ROC) analysis was firstly used to
determine the NT cut‐off with the highest sensitivity and specificity
for the prediction of congenital abnormalities and, secondly, for the
TABLE 3 Submicroscopic aberrations detected by CMA in the study
population
Microscopic chromosomal arrays
N
(total)
n
(p95‐
p99)
n
(≥p99)
‐ Del 2q13 ‐Pierre Robin sequence 1 1
‐ Dup 10q21.3 1 1
‐ Del 3p26.3 1 1
‐ Dup 7q21.12q21.13 1 1
‐ Del 4q28.3 and dup 7p22.3 1 1
‐ Dup 49 kb at 11p14.1 1 1
‐ Interstitial 6q del 1 1
‐ Del 15q11.2 ‐ Prader/Angelman Syndrome 1 1
‐ 8p23.1 microdeletion syndrome 1 1
‐ 22q11 deletion – Di George syndrome
‐ Dup 22q11
‐ Del sub telomere region in 18p
5
1
1
5
1
1
‐ Dup of 4.1 Mb in 2p25.3 and del of 6.2 Mb
in8p23.3p23.1
1 1
‐ Del of 715 kb in 9q34.3 1 1
‐ Dup of 263 kb at 10p12.31 and dup of 85 kb
at 17p13.2
1 1
‐ Unbalanced translocation chrom 11 and
chrom 14*
1 1
‐ 9p del syndrome 1 1
‐ Dup of ~435 kb in 11q13.4 1 1
‐ Unbalanced translocation chrom 4 and chrom
18*
1 1
‐ Dup 6p25.3 (6p25.3(1,519,929‐1,708,856)x3
pat)
1 1
‐ XY translocation, Yp11.2p11.31 translocated
in Xp22.33
1 1
‐ 47,XY,+i(12)(p10)de novo 1 1
‐ 17q21.31 microdeletion syndrome 1 1
‐ 46,XY der(11)t(2;11)(p11.2;q2.4)pat
‐ Del 13q13.3 q33.3
1
1
1
1
‐ Unbalanced translocation partial monosomy
13p, partial trisomy 16p*
1 1
‐ Del 732kb 5p* 1 1
‐ Del 15q 26.2 1 1
‐ Del 4p16.2 1 1
‐ 918 kb dup 10q11.21 and 110 kb del
22q12.3
1 1
‐ Dup in 13q12.11 and 245 kb dup in Xp22.33 1 1
‐ 183 kb del in 7p15.3 1 1
‐ Dup 11p15.4(4,041,195‐4,239,042)x4mat 1 1
‐ 46,XY, der(11)t(2;11) (p11.2;q2.4) 1 1
38 8 30
*Breakpoints for these cases could not be retrieved.
TABLE 4 Other karyotype abnormalities in the study population
Karyotype abnormality N (total) n (p95‐p99) n (≥p99)
Aneuploidy 101 12 89
45,X 74 4 70
Triploidy 8 2 6
47,XXY 7 3 4
Trisomy 22 4 1 3
Trisomy 15 2 2
Trisomy 16 2 1 1
Trisomy 7 1 1
Trisomy 11 1 1
Trisomy 19 1 1
Tetrasomy 9 1 1 0
Balanced translocations 3 3
46,XX,t(5;6) 1 1
46,XX,t(1:9)(q32;q13.3) 1 1
46,XY,inv(1)(p11;q21) 1 1
104 12 92
TABLE 5 NT measurement in fetuses with RASopathies in the study
population
RASopathy n NT mm (median, range)
Noonan syndrome 18 5.9 (3.1–14.3)
Leopard syndrome 1 12.0
Cardio‐facio‐cutaneous syndrome 1 16.7
All 20 6.6 (3.1–16.7)
BARDI ET AL. 5prediction of adverse pregnancy outcome (termination of pregnancy
or pregnancy loss). The best cut‐off was at a NT measurement of
3.55 mm; this gave an Area Under the Curve (AUC) of 0.791 with a
sensitivity of 74% and specificity of 71% (Figure 2). The best cut‐off
for the prediction of adverse pregnancy outcome was at a NT mea-
surement of 3.6 mm, with an AUC of 0.779 with a sensitivity of
70% and specificity of 75% (Figure 3).4 | DISCUSSION
This study shows that 43% of fetuses with NT≥95th percentile had
either genetic or structural abnormalities, with rates increasing propor-
tionally to the degree of NT enlargement. Sixty‐two percent of fetuses
with NT≥99th percentile had an abnormality and the percentage
increased from 43.3% (n=213) for NT between 3.5 and 4.9 mm to
79.6% (n=129) for NT≥8.0 mm.
Of the fetuses with an NT between 95th and 99th percentile one in
five had a congenital abnormality. The high rate of abnormalities in
this group is most likely due to the fact that especially cases with a
NT>95th percentile and with an increased CT risk were referred to a
FMU. This selection bias may result in an overestimation of the true
TABLE 6 Structural abnormalities in the study population divided by organ system and moment of diagnosis
Structural
anomaly
Referral
Total n
(%)
At NT
measurement n (%)
Time TOP#
Mean (n)
<18 weeks
n (%)
Time TOP#
Mean (n)
>18 weeks
n (%)
Time TOP§
Mean (n)
After birth
n (%)
Unknown
n (%)
Cardiac 74 (3.9) 21 (28.4) 15+1 (9) 20 (27) 17+3 (7) 26 (35.1) 22+6 (2) 5 (6.8) 2 (6.8)
Urogenital tract 20 (1.04) 4 (20) 14+3 (2) 2 (10) 19+3 (1) 12 (60) ‐ 2 (10) 0
Body stalk & CNS 11 (0.6) 4 (36.4) 15+1 (3) 2 (18.2) 18+3 (1) 2 (18.2) ‐ 1 (9.1) 2 (18.2)
Skeletal 13 (0.7) 9 (69.2) 15+3 (7) 4 (30.8) 17+5 (2) 0 0 0
Abdominal wall 9 (0.5) 7 (77.8) 15+3 (3) 1 (11.1) ‐ 1 (11.1) ‐ 0 0
Pulmonary 7 (0.4) 1 (14.3) 18+3 (1) 2 (28.6) ‐ 2 (28.6) ‐ 1 (14.3) 1 (14.3)
Digestive tract 5 (0.5) 0 0 1 (20.0) ‐ 3 (60.0) 1 (20.0)
Facial 1 (0.3) 0 1 (100) ‐ 0 0 0
Other* 9 (0.5) 7 (77.8) 12+6 (2) 0 0 0 2
MCA¶ 29 (1.6) 25 (86.2) 13+6 (18) 4 (13.4) 17+2 (3) ‐ ‐ ‐
Total 178 79 (44.4) 15+3 (45) 36 (20.2) 18+2 (14) 44 (24.7) 22+6 (2) 12 (6.7) 8 (4.5)
*Others: 1 case siamese twins, 1 case limb body wall anomaly, 1 case hydrops with AVSD and multiple heart anomalies, 1 case with heterotaxia, 1 case with
teratoma, 1 with case severe hydrothorax, 3 cases with hydrops because of unspecified heart anomalies.
¶Multiple congenital anomalies: (parents declined genetic testing in 8 fetuses. No anomaly was found by karyotyping, QF‐PCR and MCA in 18 cases. 2
fetuses with neuromuscular disorders and 1 case with normal karyotype and failed MCA investigation which was not repeated).
§Mean timing of termination of pregnancy (TOP) in weeks.
6 BARDI ET AL.prevalence of abnormalities in this group, limiting the extrapolation of
the data to the whole group of fetuses with NT between 95th and 99th
percentile. Nevertheless, our results are in keeping with previous stud-
ies confirming the strong relationship between degree of NT thickness
and congenital abnormalities.1,16-18FIGURE 2 ROC curve all congenital abnormalities [Colour figure can
be viewed at wileyonlinelibrary.com]
FIGURE 3 ROC curve pregnancy outcome [Colour figure can be
viewed at wileyonlinelibrary.com]Chromosomal abnormalities (n=560) were diagnosed in 29.4% of
the fetuses with NT≥95th percentile. Of these, 456 (81%) were com-
mon trisomies. Other chromosomal unbalances were detected in 104
(5.4%) fetuses and 38 single‐gene disorders in an additional 2% of
fetuses.
BARDI ET AL. 74.1 | Chromosomally abnormal fetuses
The rate of chromosomal abnormalities in fetuses with NT≥3.5mm
(43%) was higher in this study than that reported by Srebniak and col-
leagues19 (38%). We confirm that, after trisomy 21, 18 and 13, mono-
somy X (3.8%) is the next most common numerical chromosomal
aberration. Even though this abnormality is usually amenable to first
trimester diagnosis when accompanied by a very large nuchal fluid
accumulation, this implies that a scan needs to be performed. Since
inThe Netherlands cfDNA is offered as first tier screening test without
sex chromosomal analysis, and because a scan is usually performed to
date the pregnancy at a very early gestational age (9‐10 weeks), it can
be speculated that of the 74 cases of monosomy X in this study, the
majority may have remained undetected, had the current screening
paradigm been used. The same would apply to the 8 cases of triploidy
in the cohort.
Chromosomal microarray analysis revealed submicroscopic aberra-
tions <5Mb in 3% of the pregnancies with NT≥3.5mm. The frequency
of copy number variants (CNVs) in these cases varies considerably in
the literature from 0–15%, according to the unselected or selected
nature of the pregnant population.20-23 In our study, CMA was not
consistently performed in all cases with enlarged NT, but primarily in
cases with ultrasound abnormalities and more systematically in the last
years of the study. This may explain our lower rate of pathogenic
CNVs, in comparison with the meta‐analysis by Grande and colleagues,
reporting 6%‐9% CNVs detected by CMA in fetuses with increased
nuchal translucency and with ultrasound abnormalities.24 However
our rate of CNV is similar to the 1.6% pathogenic structural unbal-
anced chromosome aberration plus 0.8 % susceptibility locus for
neurodevelopmental disorders reported by Srebniak.19 With advances
in laboratory techniques, cfDNA can now detect a wider range of chro-
mosomal abnormalities than only the common trisomies for which it
was initially offered.7 These include deletions and duplications
>10Mb and maternal sex chromosome abnormalities.25 If in our cohort
genome‐wide cfDNA had been performed instead of the CT, we esti-
mate that 4 (10.5%) of the 38 atypical chromosomal aberrations could
have potentially been detected. However, as detection rates reported
to date are very variable this may be an optimistic assessment.
The use of genome‐wide cfDNA panels impacts the usually
extremely low false positive rate of the test, due to cases of confined
placental mosaicism (CPM).12 CPM is especially common in sex chro-
mosomes, particularly monosomy X,26 and rare autosomal trisomies
such as trisomy 7, 16, 8 and 20. This also negatively affects the posi-
tive predictive value of the screening test, which inevitably
decreases.12,26,27 The net result is that genome‐wide cfDNA under-
mines the main advantage of this screening test above the CT, which
is to reduce the need for invasive testing. Equally concerning is that
parents must face a stressful time of insecurity for conditions of
uncertain and often limited clinical significance.28 Finally, although
there is a trend towards decreasing costs of cfDNA, these are still
high. The use of extended panels will inevitably also add to the costs
related to the higher screen positive rate requiring, besides more inva-
sive procedures, also extensive genetic counseling. This can beextremely challenging since many incidental findings are rare and their
natural history is not yet understood and cannot be predicted.25 Alter-
natively to universal screening by cfDNA, some authors have sug-
gested a strategy of cfDNA contingent to first‐line screening by CT
as more cost effective.29 In this case, women with high risk at the
CT are referred for invasive testing and women with intermediate risk
(cut‐off depending on financial means) are offered cfDNA.29-32 This
results in higher sensitivity and specificity at considerably lower costs.4.2 | Chromosomally normal fetuses
Of all fetuses with NT>95th percentile and normal karyotype, 9.3%
had structural abnormalities. This study confirms that the prevalence
of structural abnormalities ranges between 3% and 50%,18 depending
on the NT cut‐off and on the study population. The most common
abnormalities are cardiac,33,34 followed by pulmonary, gastrointestinal,
genitourinary and musculoskeletal2,3 abnormalities. Since about half of
all structural abnormalities are amenable to early diagnosis,35-38 ultra-
sound investigation is essential, regardless of the chosen screening
paradigm. In our study, 44.4% of structural abnormalities were diag-
nosed at the time of NT measurement and an additional 20.2% at
referral and in any case before the 20‐week scan. Thus, 64.6% of
structural abnormalities would have potentially been missed in the
first trimester if cfDNA had been used as first trimester screening test
without an early ultrasound scan.
Overall, of the 821 congenital abnormalities, 34% would have
remained undiagnosed in the first trimester if cfDNA had been offered
as the only screening test. These include sex chromosome abnormali-
ties (n=81), triploidy (n=7) single gene disorders (n=38), submicroscopic
aberrations <5Mb (n=38) and structural abnormalities diagnosed in the
first trimester (n=115).
Our study confirms the strong association between nuchal fluid
accumulation and RASopathies, of which Noonan syndrome is the
most common.39 This group represented 52% of the single gene disor-
ders diagnosed in the cohort. Of note is that all the fetuses with
RASopathies had all NT larger than 3.1 mm. in a recent study
RASopathy analysis is recommended in all cases of NT ≥5mm, even
in the absence of additional markers.394.3 | NT cut‐off
The most widely used NT cut‐off as indication for additional ultra-
sound and genetic investigations is 3.5mm, corresponding to the
99th centile.40 Our results support that this cut‐off has the highest
sensitivity and specificity to detect congenital abnormalities. However,
23.4% of abnormalities were found in pregnancies with a NT measure-
ment between 95th and 99th percentile. Recently, a cut‐off of 3.0mm
has been recommended as indication for CMA.41 Although using
lower cut‐offs may be less cost‐effective, the choice of undergoing
invasive testing at lower NT measurements should be left to parents’
discretion and the indication for CMA be primarily determined by
the presence of structural abnormalities.
8 BARDI ET AL.In conclusion, although cfDNA has proven to be superior to the CT
for the detection of common trisomies, chromosomal abnormalities
are less frequent than structural abnormalities in the general popula-
tion. Considering the fact that structural abnormalities, and especially
many lethal ones, can already be diagnosed in the first trimester of
pregnancy, an ultrasound scan remains an essential part of the screen-
ing paradigm. In a holistic first trimester screening approach genotyp-
ing should be coupled to phenotyping. Finally, new improvements in
cfDNA panel coverage are promising for the future, but their clinical
utility is still unclear and needs further investigation.
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